AAPL   373.85 (+2.68%)
MSFT   208.83 (+1.24%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.44 (-0.06%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
TSLA   1,208.66 (+0.00%)
AMD   53.40 (+2.03%)
T   30.55 (+1.56%)
ACB   12.27 (+0.00%)
F   6.20 (+2.48%)
DIS   113.82 (+1.46%)
BAC   23.80 (+2.19%)
NFLX   493.81 (+3.55%)
AAPL   373.85 (+2.68%)
MSFT   208.83 (+1.24%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.44 (-0.06%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
TSLA   1,208.66 (+0.00%)
AMD   53.40 (+2.03%)
T   30.55 (+1.56%)
ACB   12.27 (+0.00%)
F   6.20 (+2.48%)
DIS   113.82 (+1.46%)
BAC   23.80 (+2.19%)
NFLX   493.81 (+3.55%)
AAPL   373.85 (+2.68%)
MSFT   208.83 (+1.24%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.44 (-0.06%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
TSLA   1,208.66 (+0.00%)
AMD   53.40 (+2.03%)
T   30.55 (+1.56%)
ACB   12.27 (+0.00%)
F   6.20 (+2.48%)
DIS   113.82 (+1.46%)
BAC   23.80 (+2.19%)
NFLX   493.81 (+3.55%)
AAPL   373.85 (+2.68%)
MSFT   208.83 (+1.24%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.44 (-0.06%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
TSLA   1,208.66 (+0.00%)
AMD   53.40 (+2.03%)
T   30.55 (+1.56%)
ACB   12.27 (+0.00%)
F   6.20 (+2.48%)
DIS   113.82 (+1.46%)
BAC   23.80 (+2.19%)
NFLX   493.81 (+3.55%)
Log in

ASX:RNORhinomed Stock Price, Forecast & News

A$0.07
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.07
Now: A$0.07
A$0.07
50-Day Range
A$0.07
MA: A$0.07
A$0.07
52-Week Range
A$0.06
Now: A$0.07
A$0.41
Volume452,773 shs
Average Volume122,418 shs
Market Capitalization$12.35 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rhinomed Limited, a medical technology company, researches, develops, and commercializes consumer and medical devices. The company identifies, acquires, and commercializes late stage therapeutic delivery technologies. It markets Turbine, a nasal dilator designed to assist to breathe easier during aerobic exercise; and Mute, a nasal dilator designed to enhance sleep quality by breathing more and snoring less. The company also develops Breathing Space Health that comprises of a range of wellness programs designed to help people get to sleep. In addition, it develops Sleep Apnea, a clinical trial solution to mild and moderate sleep apnea; creates drug delivery platform for delivering medication into the nose in an inhaled form or via a trans-dermal or trans-mucosal method; and researches and develops current programs focuses on olfactory pathway and wearable technology. The company sells its products through wholesalers, retail stores, and clinics, as well as online in the United States, Canada, the United Kingdom, Taiwan, Australia, and New Zealand. It serves clinicians and health care organizations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-84160900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.67 million
Cash FlowA$0.02 per share
Book ValueA$0.04 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$12.35 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RNO News and Ratings via Email

Sign-up to receive the latest news and ratings for RNO and its competitors with MarketBeat's FREE daily newsletter.

Rhinomed (ASX:RNO) Frequently Asked Questions

How has Rhinomed's stock been impacted by COVID-19 (Coronavirus)?

Rhinomed's stock was trading at A$0.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RNO shares have decreased by 33.6% and is now trading at A$0.07. View which stocks have been most impacted by Coronavirus.

How were Rhinomed's earnings last quarter?

Rhinomed Ltd (ASX:RNO) announced its earnings results on Thursday, February, 28th. The company reported ($0.02) EPS for the quarter. View Rhinomed's earnings history.

Has Rhinomed been receiving favorable news coverage?

News stories about RNO stock have trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Rhinomed earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Rhinomed.

Who are some of Rhinomed's key competitors?

Who are Rhinomed's key executives?

Rhinomed's management team includes the following people:
  • Mr. Michael Johnson, CEO, MD & Director
  • Mr. Sean Slattery, Chief Financial Officer
  • Mr. Phillip Allen Hains, Company Sec.

What is Rhinomed's stock symbol?

Rhinomed trades on the ASX under the ticker symbol "RNO."

What is Rhinomed's stock price today?

One share of RNO stock can currently be purchased for approximately A$0.07.

How big of a company is Rhinomed?

Rhinomed has a market capitalization of $12.35 million and generates $3.67 million in revenue each year.

What is Rhinomed's official website?

The official website for Rhinomed is www.rhinomed.com.au.

How can I contact Rhinomed?

Rhinomed's mailing address is 97 Green St, RICHMOND, VIC 3121, Australia. The company can be reached via phone at +61-3-84160900.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.